Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
NCT ID: NCT01749943
Last Updated: 2013-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21 participants
OBSERVATIONAL
2012-07-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Also to establish a standardized strength testing procedure for key lower limb muscle groups using a HHD fo research and clinical purposes in Multiple Sclerosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EDSS Score 0-3.5
21 Subjects Total : 7 with normal to mildly limited walking
No interventions assigned to this group
EDSS Score 4.0-5.5
21 Subjects total: 7 subjects with moderately limited walking ability.
No interventions assigned to this group
EDSS Score 6.0-7.5
21 Subjects total: 7 subjects with severely limited walking ability
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No Multiple Sclerosis exacerbation 30 days prior to screening
* No change in disease modifying therapy for 30 day prior to screening
Exclusion Criteria
* Endocarditis, pericarditis o rother unstable heart disease
* Cardiac surgery or myocardial infarction in the last 3 months
* Decompensated congestive heart failure
* Severe aortic stenosis
* Severe pulmonary hypertension
* Pulmonary embolus or infarction in the last 6 months
* Uncontrolled hypertension by history or by screening or baseline diastolic blood pressure \>170 or systolic blood pressure \>105
* Concomitant neurodegenerative neurological disease such as Amyotrophic Lateral Sclerosis (ALS) Parkinsons or hemiplegic stroke
* females who are pregnant
* Cognitive deficits that would interfere with the subjects's ability to give informed consent or preform study testing
* Painful orthopedic condition affecting the lower limbs
* Any other serious and/or unstable medical condition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Brown, Theodore R., M.D., MPH
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theodore R Brown, MD
Role: PRINCIPAL_INVESTIGATOR
MS Center at Evergreen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MS Center at Evergreen Hospital
Kirkland, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US-AVX-11-10213
Identifier Type: -
Identifier Source: org_study_id